^
    10d
    CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Chinese PLA General Hospital | Recruiting --> Active, not recruiting | N=15 --> 9 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment closed • Enrollment change • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12
    |
    Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • KRAS-EphA-2-CAR-DC
    2ms
    MATCHPOINT: Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Florida | Active, not recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    Keytruda (pembrolizumab)
    2ms
    NATASHA: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (clinicaltrials.gov)
    P2, N=53, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • HER-2 pulsed DC1
    3ms
    LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma (clinicaltrials.gov)
    P2, N=27, Completed, Istari Oncology, Inc. | Active, not recruiting --> Completed | N=56 --> 27
    Trial completion • Enrollment change • Checkpoint inhibition • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    lerapolturev (PVS-RIPO)
    3ms
    Dendritic Cell Activating Scaffold in Melanoma (clinicaltrials.gov)
    P1, N=23, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed
    Trial completion
    3ms
    ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=55, Active, not recruiting, Orionis Biosciences Inc | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    ORB-011
    4ms
    COV-IMMUNO: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (clinicaltrials.gov)
    P3, N=195, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2025 --> Dec 2025
    Trial completion date
    |
    IMM-101
    4ms
    NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • NC410
    5ms
    Lerapolturev in Recurrent Malignant Glioma (clinicaltrials.gov)
    P2, N=121, Completed, Istari Oncology, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    lomustine • lerapolturev (PVS-RIPO)
    5ms
    MATCHPOINT: Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of Florida | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab)
    5ms
    NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression. (PubMed, J Immunol)
    The proportion of collagen-1-positive cells was highest among tumor cells and tumor-infiltrating immune cells versus stromal immune cells, raising the potential role of tumor-associated collagen limiting immune cell infiltration into tumor. Our results support further evaluation of circulating and tumor-associated collagen products and LAIR-1 and LAIR-2 as prognostic biomarkers in advanced OC and as biomarkers for clinical response to NC410 and to other collagen- and LAIR-directed therapies.
    Journal
    |
    LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    |
    NC410
    7ms
    STU-2021-0657: CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Texas Southwestern Medical Center | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 negative
    |
    PD-L1 IHC 22C3 pharmDx
    |
    pegylated liposomal doxorubicin • CDX-1140 • Mobista (CDX-301)